Expasy logo

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot Q06787: Variant p.Arg546His

Fragile X messenger ribonucleoprotein 1
Gene: FMR1
Feedback?
Variant information Variant position: help 546 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: help LB/B The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance

Residue change: help From Arginine (R) to Histidine (H) at position 546 (R546H, p.Arg546His). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: help Change from large size and basic (R) to medium size and polar (H) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: help 0 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Other resources: help Links to websites of interest for the variant.


Sequence information Variant position: help 546 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: help 632 The length of the canonical sequence.
Location on the sequence: help LRRGDGRRRGGGGRGQGGRG R GGGFKGNDDHSRTDNRPRNP The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Sequence annotation in neighborhood: help The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.
TypePositionsDescription
Chain 1 – 632 Fragile X messenger ribonucleoprotein 1
Region 419 – 632 Interaction with RANBP9
Region 443 – 632 Disordered
Region 534 – 548 RNA-binding RGG-box
Modified residue 534 – 534 Asymmetric dimethylarginine; alternate
Modified residue 534 – 534 Omega-N-methylarginine; alternate
Modified residue 539 – 539 Asymmetric dimethylarginine; alternate
Modified residue 539 – 539 Omega-N-methylarginine; alternate
Modified residue 544 – 544 Asymmetric dimethylarginine; alternate
Modified residue 544 – 544 Omega-N-methylarginine
Modified residue 544 – 544 Omega-N-methylarginine; alternate
Modified residue 546 – 546 Asymmetric dimethylarginine; alternate
Modified residue 546 – 546 Omega-N-methylarginine; alternate
Alternative sequence 426 – 632 EVDQLRLERLQIDEQLRQIGASSRPPPNRTDKEKSYVTDDGQGMGRGSRPYRNRGHGRRGPGYTSGTNSEASNASETESDHRDELSDWSLAPTEEERESFLRRGDGRRRGGGGRGQGGRGRGGGFKGNDDHSRTDNRPRNPREAKGRTTDGSLQIRVDCNNERSVHTKTLQNTSSEGSRLRTGKDRNQKKEKPDSVDGQQPLVNGVP -> LQQRKRGRASCAEETDGGVEGEEEDKEEEDVEEASKETTITPEQIIVHVIQERLKEEQQMDPFRSELTAIMKGVSTLKHYRIPPVKVVGCARVKIVTRRKRSQTAWMVSNHS. In isoform 10 and isoform 11.
Mutagenesis 544 – 544 R -> K. Reduces arginine methylation by 80%.
Mutagenesis 546 – 546 R -> K. Slightly reduced methylation.



Literature citations
Novel point mutation within intron 10 of FMR-1 gene causing fragile X syndrome.
Wang Y.-C.; Lin M.-L.; Lin S.J.; Li Y.-C.; Li S.-Y.;
Hum. Mutat. 10:393-399(1997)
Cited for: VARIANT HIS-546;
Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.